Role of Maintenance Therapy in Ovarian Cancer

Video

MMH_Ovarian_ClinConsult_Seg03_Role
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
      Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
      Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
      The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
      Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
      Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
      Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
      Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
      Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
      Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
      Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
      Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
      Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
      Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
      Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian Cancer
      Related Content
      The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

      Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

      Roman Fabbricatore
      April 2nd 2025
      Article

      The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

      Kathleen N. Moore, MD, MS
      March 17th 2025
      Podcast

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

      Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

      Russ Conroy
      March 19th 2025
      Article

      Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

      Target Folate Receptor Alpha in Ovarian Cancer?

      Target Folate Receptor Alpha in Ovarian Cancer?

      Dmitriy Zamarin, MD, PhD
      September 17th 2018
      Podcast

      Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

      Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

      Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

      Megan Hollasch
      March 17th 2025
      Article

      A phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.

      Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.

      Rina-S Elicits Encouraging Antitumor Activity in Advanced Ovarian Cancer

      Russ Conroy
      March 17th 2025
      Article

      Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.